Use of bisphosphonates for the treatment of stress fractures in athletes

被引:23
作者
Shima, Yosuke [2 ,4 ]
Engebretsen, Lars [1 ,3 ]
Iwasa, Junji [2 ]
Kitaoka, Katsuhiko [4 ]
Tomita, Katsuro [4 ]
机构
[1] Ullevaal Univ Hosp, Orthoped Ctr, N-0407 Oslo, Norway
[2] Norwegian Sch Sport Sci, Oslo Sports Trauma Res Ctr, N-0806 Oslo, Norway
[3] Univ Oslo, Fac Med, N-0407 Oslo, Norway
[4] Kanazawa Univ, Dept Orthoped Surg, Kanazawa, Ishikawa 9208641, Japan
关键词
Bisphosphonates; Treatment; Stress fracture; Microdamage; Bone remodeling; SUPPRESSED BONE TURNOVER; ACUTE-PHASE RESPONSE; ZOLEDRONIC ACID; MICRODAMAGE ACCUMULATION; BIOMECHANICAL PROPERTIES; FEMORAL-HEAD; RISK-FACTORS; TRAUMATIC OSTEONECROSIS; TRANSIENT OSTEOPOROSIS; PAMIDRONATE DISODIUM;
D O I
10.1007/s00167-008-0673-0
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
A literature review was performed to investigate the potential role of bisphosphonates for the treatment of stress fractures in athletes. Given the inhibitory action on osteoclast-mediated bone resorption, short-term suppression of bone remodeling using bisphosphonates could potentially treat stress fractures and prevent stress fractures from becoming regular fractures. To date, while there are some animal studies showing the scientific basis of bisphosphonates on stress fractures, there is still no conclusive evidence to prove any effect of bisphosphonates on stress fracture healing in humans. Further well-designed clinical trials should be carried out to establish their usefulness and safety. Until the results are available, it is prudent to limit the use of bisphosphonates for the treatment of stress fractures.
引用
收藏
页码:542 / 550
页数:9
相关论文
共 85 条
  • [1] THE ACUTE-PHASE RESPONSE AFTER BISPHOSPHONATE ADMINISTRATION
    ADAMI, S
    BHALLA, AK
    DORIZZI, R
    MONTESANTI, F
    ROSINI, S
    SALVAGNO, G
    LOCASCIO, V
    [J]. CALCIFIED TISSUE INTERNATIONAL, 1987, 41 (06) : 326 - 331
  • [2] Safety and efficacy of bisphosphonates beyond 24 months in cancer patients
    Ali, SM
    Esteva, FJ
    Hortobagyi, G
    Harvey, H
    Seaman, J
    Knight, R
    Costa, L
    Lipton, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) : 3434 - 3437
  • [3] Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate
    Allen, Matthew R.
    Iwata, Ken
    Phipps, Roger
    Burr, David B.
    [J]. BONE, 2006, 39 (04) : 872 - 879
  • [4] A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair
    Amanat, N
    Brown, R
    Bilston, LE
    Little, DG
    [J]. JOURNAL OF ORTHOPAEDIC RESEARCH, 2005, 23 (05) : 1029 - 1034
  • [5] Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair
    Amanat, Negin
    McDonald, Michelle
    Godfrey, Craig
    Bilston, Lynne
    Little, David
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (06) : 867 - 876
  • [6] Effect of short-term treatment with alendronate on ulnar bone adaptation to cyclic fatigue loading in rats
    Barrett, Jennifer G.
    Sample, Susannah J.
    McCarthy, Jenna
    Kalscheur, Vicki L.
    Muir, Peter
    Prokuski, Laura
    [J]. JOURNAL OF ORTHOPAEDIC RESEARCH, 2007, 25 (08) : 1070 - 1077
  • [7] Bauss Frieder, 2004, Journal of Pharmacological and Toxicological Methods, V50, P25, DOI 10.1016/j.vascn.2003.11.003
  • [8] A 12-month prospective study of the relationship between stress fractures and bone turnover in athletes
    Bennell, KL
    Malcolm, SA
    Brukner, PD
    Green, RM
    Hopper, JL
    Wark, JD
    Ebeling, PR
    [J]. CALCIFIED TISSUE INTERNATIONAL, 1998, 63 (01) : 80 - 85
  • [9] Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function
    Berenson, JR
    Rosen, L
    Vescio, R
    Lau, HS
    Woo, M
    Sioufi, A
    Kowalski, O
    Knight, RD
    Seaman, JJ
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (04) : 285 - 290
  • [10] Osteonecrosis of the jaw - Do biphosphonates pose a risk?
    Bilezikian, John P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) : 2278 - 2281